Skip to main content

Table 6 Amyloid-related imaging abnormality findings by APOE ε4 genotype and severity of amyloid-related imaging abnormalities-vasogenic edema events

From: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

  Placebo
(n = 266)
Gantenerumab 105 mg
(n = 271)
Gantenerumab 225 mg
(n = 260)
ARIA-E 2 (0.8%) 18 (6.6%) 35 (13.5%)a
 0ε4 patients 2 (2.5%) 1 (1.8%) 11 (11.0%)
 1ε4 patients 0 6 (5.4%) 24 (15.0%)
 2ε4 patients 0 11 (10.7%)
Maximum severity of ARIA–E, mean (±SD)b 4.0 (4.2) 4.0 (2.1) 5.7 (6.9)
ARIA-H 35 (13.2%) 62 (22.9%) 42 (16.2%)a
 0ε4 patients 4 (5.1%) 7 (12.3%) 11 (11.0%)
 1ε4 patients 19 (14.2%) 22 (19.8%) 31 (19.4%)
 2ε4 patients 12 (22.6%) 33 (32.0%)
  1. ARIA-E Amyloid-related imaging abnormalities-vasogenic edema, ARIA-H Amyloid-related imaging abnormalities-hemosiderin
  2. aBy design, there were no APOE 2ε4 patients in the gantenerumab 225 mg arm
  3. bARIA-E rating scale 28